A proof of efficacy study of BIO 11006 in non small cell lung cancer
Phase of Trial: Phase I
Latest Information Update: 21 Apr 2017
At a glance
- Drugs BIO-11006 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 21 Apr 2017 According to a BioMarck Pharmaceuticals media release, the company received FDA's approval to conduct the trial of BIO-11006 in adults with lung cancer.
- 20 Sep 2016 According to a BioMarck Pharmaceuticals media release, the company anticipates FDA approval and begin this study in 2017.
- 20 Jan 2016 New trial record